| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Autobiography |
| Article Title |
Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Tsutomu Nishida, Masahiko Tsujii, Hirohisa Tanimura, Shusaku Tsutsui, Shingo Tsuji, Akira Takeda, Atsuo Inoue, Hiroyuki Fukui, Toshiyuki Yoshio, Osamu Kishida, Hiroyuki Ogawa, Masahide Oshita, Ichizo Kobayashi, Shinichiro Zushi, Makoto Ichiba, Naoto Uenoyama, Yuichi Yasunaga, Ryu Ishihara, Mamoru Yura, Masato Komori, Satoshi Egawa, Hideki Iijima and Tetsuo Takehara |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Tetsuo Takehara, MD, PhD, Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. takehara@gh.med.osaka-u.ac.jp |
| Key Words |
Helicobacter pylori; Eradication; Esomeprazole; Lansoprazole; Proton pomp inhibitor |
| Core Tip |
Amoxicillin is a standard regime for Helicobacter pylori (H. pylori) eradication in Japan. Esomeprazole is a second-generation PPI that became available in 2011 in Japan. Several studies have reported eradication data comparing esomeprazole to first-generation proton pump inhibitors (PPIs), but it is not known whether the H. pylori eradication rates of esomeprazole are equal to those of lansoprazole, a first-generation PPI, under circumstances of increased resistance to clarithromycin in Japan. |
| Publish Date |
2014-04-17 13:27 |
| Citation |
Nishida T, Tsujii M, Tanimura H et al. Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan.World J Gastroenterol 2014; 20(15): 4362-4369 |
| URL |
http://www.wjgnet.com/1007-9327/full/v20/i15/4362.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v20.i15.4362 |
